News >

Avelumab Continues to Show Value in JAVELIN Merkel 200 Analyses

Angelica Welch
Published: Friday, Nov 30, 2018

Sandra P. D'Angelo, MD

Sandra P. D'Angelo, MD

In an analysis of patient-reported outcomes (PROs) of the JAVELIN Merkel 200 trial (NCT02155647) of avelumab (Bavencio), investigators found that there was a similarity in proportion of responders with metastatic Merkel cell carcinoma based on clinical and PRO endpoints.1

Moreover, an additional analysis of this study showed that avelumab was a cost-effective end-of-life treatment option for patients with metastatic Merkel cell carcinoma compared with standard of care in the United Kingdom.2

JAVELIN Merkel 200 was the basis for the FDA’s accelerated approval of avelumab for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma, including those who have not received prior chemotherapy.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication